{
    "Clinical Trial ID": "NCT03096847",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ribociclib + Letrozole Cohort A",
        "  postmenopausal women, or men; na\u00efve.",
        "  All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.",
        "INTERVENTION 2: ",
        "  Ribociclib + Letrozole Cohort B1",
        "  premenopausal women or perimenopausal women; na\u00efve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patient is an adult,  18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines",
        "  Women and men with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.",
        "  Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive and HER2-negative breast cancer by local laboratory. Local pathology is sufficient for assessment.",
        "  Patient must have either:",
        "  Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria ).",
        "  Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease",
        "  Non-measurable disease",
        "  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 2",
        "  Exclusion Criteria",
        "  Patient who received any CDK4/6 inhibitor or any mTOR inhibitor.",
        "  Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole",
        "  Patients with current inflammatory breast cancer.",
        "  Patient has received > 1 chemotherapy for the treatment of advanced/metastatic breast cancer",
        "  Patient has received > 2 endocrine therapies for the treatment of advanced/metastatic breast cancer",
        "  Patient has central nervous system (CNS) involvement. If patient is fulfilling the following 3 criteria she/he is eligible for the trial.",
        "  completed prior therapy (including radiation and/or surgery) for CNS metastases  28 days prior to the start of study and",
        "  CNS tumor is clinically stable at the time of screening and",
        "  Patient is not receiving steroids and enzyme inducing anti-epileptic medications for brain metastases",
        "  Patient has active cardiac disease or a history of cardiac dysfunction"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole",
        "  Clinical Benefit Rate (CBR) after 24 weeks of treatment as defined by RECIST 1.1 as percentage of patients with Complete Response (CR), Partial response (PR) or Stable disease (SD) lasting 24 weeks or longer as well as patients with Non-complete response, nonprogressive disease (NCRNPD).",
        "  Time frame: At 24 weeks after last patient enrolled in trial",
        "Results 1: ",
        "  Arm/Group Title: Ribociclib + Letrozole Cohort A",
        "  Arm/Group Description: postmenopausal women, or men; na\u00efve.",
        "  All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.",
        "  Overall Number of Participants Analyzed: 307",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  CBR by week 24 (= BOR of CR or PR or SD or NCRNPD(Confirmed Best Overall Response (BOR)): 63.2        (57.5 to 68.6)",
        "  CBR by week 24 (= BOR of CR or PR or SD or NCRNPD (non-confirmed BOR): 71.7        (66.3 to 76.6)",
        "Results 2: ",
        "  Arm/Group Title: Ribociclib + Letrozole Cohort B1",
        "  Arm/Group Description: premenopausal women or perimenopausal women; na\u00efve All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily. Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly",
        "  Overall Number of Participants Analyzed: 26",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  CBR by week 24 (= BOR of CR or PR or SD or NCRNPD(Confirmed Best Overall Response (BOR)): 57.7        (36.9 to 76.6)",
        "  CBR by week 24 (= BOR of CR or PR or SD or NCRNPD (non-confirmed BOR): 69.2        (48.2 to 85.7)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 97/319 (30.41%)",
        "  ANAEMIA 4/319 (1.25%)",
        "  DISSEMINATED INTRAVASCULAR COAGULATION 1/319 (0.31%)",
        "  FEBRILE NEUTROPENIA 0/319 (0.00%)",
        "  HYPERFIBRINOLYSIS 0/319 (0.00%)",
        "  LEUKOPENIA 2/319 (0.63%)",
        "  NEUTROPENIA 2/319 (0.63%)",
        "  PANCYTOPENIA 1/319 (0.31%)",
        "  THROMBOCYTOPENIA 3/319 (0.94%)",
        "  ATRIAL FIBRILLATION 2/319 (0.63%)",
        "  BRADYARRHYTHMIA 1/319 (0.31%)",
        "  CARDIAC ARREST 1/319 (0.31%)",
        "Adverse Events 2:",
        "  Total: 50/183 (27.32%)",
        "  ANAEMIA 4/183 (2.19%)",
        "  DISSEMINATED INTRAVASCULAR COAGULATION 0/183 (0.00%)",
        "  FEBRILE NEUTROPENIA 3/183 (1.64%)",
        "  HYPERFIBRINOLYSIS 1/183 (0.55%)",
        "  LEUKOPENIA 0/183 (0.00%)",
        "  NEUTROPENIA 2/183 (1.09%)",
        "  PANCYTOPENIA 0/183 (0.00%)",
        "  THROMBOCYTOPENIA 0/183 (0.00%)",
        "  ATRIAL FIBRILLATION 2/183 (1.09%)",
        "  BRADYARRHYTHMIA 0/183 (0.00%)",
        "  CARDIAC ARREST 0/183 (0.00%)"
    ]
}